March 21, 2023 News by Margarida Maia, PhD Adult diagnostic criteria lacking at predicting future MS in children Predicting whether an asymptomatic child or adolescent with signs of demyelination on imaging scans will develop multiple sclerosis (MS) is difficult using adult diagnostic criteria, a small study found. The findings highlight the need for more suitable criteria for pediatric patients, which could let them begin treatment…
March 20, 2023 News by Margarida Maia, PhD No rise in MS patients’ risk of relapse seen with fertility treatments Disease relapses are no more likely in women with multiple sclerosis (MS) after fertility treatment than they were before such treatment, a study found. Researchers also observed that almost half of the women receiving fertility treatment were on disease-modifying MS therapies, which may have helped to keep a…
March 20, 2023 News by Patricia Inacio, PhD Half of US neurologists expect to test Briumvi in the next 6 months Most neurologists in the U.S. are aware of the recent approval of Briumvi (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (MS) and about half anticipate testing the therapy in the next six months,Ā according to anĀ analysisĀ by market research companyĀ Spherix Global Insights. The therapy, developed…
March 17, 2023 News by Steve Bryson, PhD Vitamin D receptor defines 2 distinct lines of immune cells: Early study The body has two distinct lineages of immune cells that can be distinguished by the presence or absence of the vitamin D receptor, a preclinical study reports. The findings shed more light on how vitamin D fine-tunes immune responses and may help researchers better understand the link between vitamin…
March 17, 2023 News by Steve Bryson, PhD Energy metabolite has potential to treat MS, autoimmune conditions Supplementation with phosphoenolpyruvate (PEP), a molecule produced during cellular energy generation, eased the signs and symptoms of multiple sclerosis (MS) in a mouse model of the disease, a study revealed. The metabolite inhibited a protein called JunB, which blocked the production of the pro-inflammatory molecule interleukin-17 (IL-17) and suppressed…
March 16, 2023 News by Mary Chapman Online medical cannabis clinic for MS pain management opens in UK The Kanabo Group has established what it claims is the U.K.ās first online medical cannabis clinic to help people with multiple sclerosis and other conditions manage chronic pain. Called Treat It, the clinic is expected to help those whose conventional pharmaceutical medicines are ineffective or those…
March 16, 2023 News by Marisa Wexler, MS ‘A Campbell Never Quits’ podcast coming in March for MS awareness A new podcast series called “A Campbell Never Quits” is telling the life story of Tyler Campbell, a patient advocate who was diagnosed with multiple sclerosis (MS) during his junior year at college. “The podcast aims to appeal to sports fans, people living with MS, and anyone who appreciates…
March 15, 2023 News by Patricia Inacio, PhD ModeX teams up with Merck to develop MDX-2201 vaccine for EBV A new collaboration between ModeX Therapeutics and Merck, known as MSD outside North America, is expected to advance the development of ModeX’s MDX-2201, an investigational vaccine targeting the Epstein-Barr virus (EBV). A history of infection with EBV ā known for causing infectious mononucleosis, or mono, and certain…
March 15, 2023 News by Marisa Wexler, MS Analyzing MS brain scans could further research into COVID-19 Because people with multiple sclerosis (MS) usually undergo regular MRI scans to image their brains, their data could help researchers learn more the long-term effects of COVID-19 on brain tissue. Thatās the argument by a team of researchers in the paper, āMultiple sclerosis as a…
March 14, 2023 News by Margarida Maia, PhD Higher blood levels of Ocrevus lower confirmed disability progression risk Higher blood levels of Ocrevus (ocrelizumab) is associated with a significantly lower risk of confirmed disability progression during treatment in people with relapsing andĀ progressiveĀ forms of multiple sclerosis (MS), according to an analysis of data from three Phase 3 clinical trials. Notably, the lower disability progression rates reported in…
March 14, 2023 News by Marisa Wexler, MS Treatments with electrical nerve stimulation ease pain in small trial Transcutaneous electrical nerve stimulation (TENS) and interferential currents (IFC) ā both interventions apply electrical stimulation through electrodes placed on the skin ā can help to ease pain in people with multiple sclerosis (MS), according to results from a small clinical trial. Results suggested that, while both treatments can reduce…
March 13, 2023 News by Andrea Lobo, PhD WHO asked to add 3 MS treatments to its list of ‘essential medicines’ Aiming to promote equitable accessĀ toĀ multiple sclerosis (MS) treatments worldwide, an international MS alliance is asking that threeĀ disease-modifying therapies (DMTs) be added to the World Health Organization’s (WHO) list of essential medicines. Inclusion on the WHO list is considered an important if “initial” step in assuring that helpful treatments…
March 13, 2023 News by Mary Chapman Neural Sleeve developer Cionic names its 1st Center of Excellence Cionic ā developer of the Neural Sleeve for people with multiple sclerosis (MS) and other conditions that affect mobility ā has chosen the Shirley Ryan AbilityLab as the inaugural location for its Center of Excellence program. The Chicago-based facility has been named the nation’s top physical medicine and…
March 10, 2023 News by Marisa Wexler, MS Stem cell therapy MSC-NP can ease inflammatory activity in brain cells MSC-NP, a form of stem cell therapy that’s currently in early clinical trials for multiple sclerosis (MS), can reduce the inflammatory activity of brain immune cells called microglia, according to a new study. The therapy is known to reduce disease severity and improve myelin regeneration in animal models of…
March 10, 2023 News by Andrea Lobo, PhD MS Australia supporting work into how diet might affect pediatric MS MS AustraliaĀ is funding a study by researchers at Curtin University into how diet might affectĀ multiple sclerosis (MS) onset in children. Led by Eleanor Dunlop, PhD, a dietitian and postdoctoral researcher at the Perth university’s School of Population Health, the study will investigate the influence different types of…
March 9, 2023 News by Lindsey Shapiro, PhD Icobrain MS, an AI tool for assessing MRI scans, being tested in UK An upcoming study will investigate how well icobrain MS, anĀ artificial intelligence (AI)-based technology,Ā can interpret MRI dataĀ from people with multiple sclerosis (MS) and how its use might influence patient care. The project, called AssistMS and led by IcometrixĀ ā the technology’s developer ā and Queen Mary University of London…
March 9, 2023 News by Marisa Wexler, MS Ocrevus and early start with aggressive treatment favored in US Neurologists in the U.S. are generally favoring more aggressive early treatment for multiple sclerosis (MS), according to an analysis by market research company Spherix Global Insights. With over a dozen therapies available in the U.S. to treat relapsing forms of MS, patients and providers have options to…
March 8, 2023 News by Lindsey Shapiro, PhD Study may help explain protective effects of pregnancy in MS A new study of women with multiple sclerosis (MS) who had previously given birth may have identified one of the mechanisms behind the lasting protective effects of pregnancy seen in MS patients. Patients who’d had children were found to have a number of differences in methylation, a type of…
March 8, 2023 News by Andrea Lobo, PhD Memory, thinking skills in MS may be aided with Mediterranean diet Following a Mediterranean diet may reduce the risk of cognitive problems, including with memory and thinking skills, in people with multiple sclerosis (MS), a preliminary study suggests. The diet includes a high intake of fish, fruits, legumes, vegetables, and healthy fats (olive oil); and a low intake of meat,…
March 7, 2023 News by Lindsey Shapiro, PhD ACTRIMS 2023: GA Depot found to ease MS disability in Phase 3 trial GA Depot, an experimental long-acting version of glatiramer acetate, significantly reduced relapse rates and prevented the development of new lesions among people with relapsing forms of multiple sclerosis, according to new data from a Phase 3 clinical trial. Disability levels also were significantly reduced with the treatment, given…
March 7, 2023 News by Lindsey Shapiro, PhD ACTRIMS 2023: RRMS treatment may ‘give patients a better choice’ New data from a Phase 2 clinical trial testing vidofludimus calcium, Immunic Therapeuticsā novel oral treatment candidateĀ for relapsing-remitting multiple sclerosis (RRMS), show promising safety and efficacy, according to the company’s chief medical officer. The therapy was found to safely reduce brain lesions and prevent disability progression in…
March 6, 2023 News by Marisa Wexler, MS ACTRIMS 2023: Can Do MS brings education, connection, activation Can Do MS has three missions for people with multiple sclerosis (MS) and their care partners ā providing education about life with the disease, building connections among people, and activating them to be proactive about managing their condition. “Those are the three pillars that our programs are built…
March 6, 2023 News by Marisa Wexler, MS ACTRIMS 2023: Delays in Ocrevus infusions not tied to greater MS activity People with multiple sclerosis (MS) being treated with Ocrevus (ocrelizumab) less frequently than the recommended every six months are not more likely to experience inflammatory disease activity, an analysis of some 360 patients whose dosing schedules changed during the COVID-19 pandemic suggests. Nicole Bou Rjeily, MD, a postdoctoral…
March 3, 2023 News by Marisa Wexler, MS ACTRIMS 2023: TG aims to make Briumvi accessible to patients Briumvi (ublituximab-xiiy) recently became the third anti-CD20 monoclonal antibody to be approved by the U.S. Food and Drug Administration (FDA) as a treatment for relapsing forms of multiple sclerosis (MS). TG Therapeutics, the therapy’s developer, is now aiming to make Briumvi the most accessible therapy in its…
March 3, 2023 News by Marisa Wexler, MS ACTRIMS 2023: Ibudilast did not lift life quality in progressive MS trial Treatment with the experimental oral therapy ibudilast (MN-166) does not significantly improve quality-of-life measures compared with a placebo among people with progressive forms of multiple sclerosis (MS), according to new data from a Phase 2 clinical trial. Analyses from the trial suggest that a marker of nerve damage…
March 3, 2023 News by Marisa Wexler, MS ACTRIMS 2023: High-dose vitamin D doesn’t reduce MS activity: Trial Taking high-dose vitamin D supplements as an add-on to standard MS treatment doesn’t reduce the risk of inflammatory disease activity for people with relapsing-remitting multiple sclerosis (RRMS), according to data from a clinical trial. The findings “suggest that prescribing higher doses of vitamin D for purposes of…
March 2, 2023 News by Marisa Wexler, MS ACTRIMS 2023: Certain eye cells tied to MS-related changes in study Certain cells in the eyes ā specifically blood vessel cells and a type of neurological immune cell called microglia ā exhibit high expression or activity of genes that have been linked to multiple sclerosis (MS), a new study reports.Ā The researchers also “identified…
March 2, 2023 News by Lindsey Shapiro, PhD ACTRIMS 2023: Documentary offers hope for the Black MS community Multiple sclerosis (MS) has long been considered a disease that mostly affects white women. But in the U.S., the numbers indicate that Black people, particularly Black women, may be more likely to develop the neurodegenerative disease than people of other racial and ethnic backgrounds. For Black individuals, this misunderstanding…
March 2, 2023 News by Marisa Wexler, MS ACTRIMS 2023: Most on Briumvi show no MS activity after 6 months More than half of the people with relapsing forms of multiple sclerosis (MS) who received Briumvi (ublituximab) in the ULTIMATE clinical trials had no signs of disease activity over the first six months of the trial ā and over 80% of participants had no disease activity for the…
March 1, 2023 News by Marisa Wexler, MS ACTRIMS 2023: HIV-positive people found to be less likely to develop MS People infected with the human immunodeficiency virus (HIV) ā including HIV-positive individuals who received antiretroviral treatment at some point after infection ā are significantly less likely to develop multiple sclerosis (MS), a new analysis suggests.Ā The decrease in MS risk was particularly pronounced…